In 2010, ten of the top ten drugs were small molecules and today, seven of the top ten drugs are recombinant proteins. This represents a multi-billion dollar sea change in the drug industry. As the portfolio of drug modalities shifts towards biopharma, Cell Line Development laboratories are forced to keep pace with the increasing pressures to express a wider format of proteins in mammalian cell lines.
From DNA to lead clone, there is a myriad of choices for Cell Line Development in terms of biology, seamless technology and core instrumentation. To navigate these choices, this webinar will present drivers needed to set up a new Cell Line Development laboratory or scale-out production, as well as discuss viable present-day solutions.
When considering the expression of classical ‘vanilla’ monoclonal antibodies versus ‘tutti frutti’ trispecific antibody formats, decisions in the delivery of the correct stoichiometry of the chains are pertinent. ATUM will present on how the Leap-In transposase technology provides a fast, efficient, robust and stable way to deliver large transgene cargo into CHO cells for the development of cell lines expressing novel therapeutic molecules.
Join this free webinar to learn more about how to maximize potential technology to accelerate workflows in Cell Line Development in order to generate high-quality cell lines.
Mark Stockdale, Amalgamator of Business and Biology, Solentim Ltd
Mark Stockdale is a keen technology pathfinder and works within Solentim to amalgamate the technical and business functions within the company. Prior to Solentim, he worked as a Group Leader at Horizon Discovery Ltd, a scientist within Lonza Biologics, Cyclacel Ltd and started his career at Pfizer. With over 15 years of professional experience in cell line development and drug discovery, his passion is to bring new technologies to bear on unmet needs and provides great insight into the future technology requirements in stable cell line development.Message Presenter
Oren Beske, Amalgamator of Business and Biology, ATUM
Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he served as the CEO of Alloy Therapeutics, Inc. a start up antibody discovery platform company. Dr. Beske received a BS in Physiology and Biochemistry from CSULB and his Ph.D. in Cell Biology from UC San Francisco.Message Presenter
Who Should Attend?
- Cell Line Development Scientists
- Head of Cell Line Development
- Technology Development Scientists
What You Will Learn
The common challenges when setting up a Cell Line Development laboratory
ATUM will present new technologies that are accelerating Cell Line Development and impacting the quality of these processes
Solentim is the trusted global leader for solutions to isolate, analyse and document the highest value cells to ensure the quality of master cell banks. Solentim provide a portfolio of proven, innovative technologies combined with our unparalleled experience to maximise regulatory / IND success. Key products include Cell Metric(R) for daily outgrowth imaging and clonality assurance and VIPS(TM) for single cell seeding, in-well assurance and daily outgrowth imaging. For more information please visit: www.solentim.com
ATUM offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors and platforms for protein and cellular engineering and production. The company exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster. For more information please visit: www.atum.bio